Dr. Sharon Orton-Gibbs authors peer-reviewed case study with results from 15 clinical cases
HOUSTON (Dec. 14, 2016) – OrthoAccel® Technologies, Inc. announces that the Journal of Clinical Orthodontics (JCO) has published results from “Accelerated Orthodontics Using Pulsatile Forces in Orthognathic Surgical Patients,” a case series demonstrating accelerated treatment when incorporating AcceleDent® into combined orthodontic and orthognathic surgery cases. In these cases orthodontists are using techniques to both straighten the teeth (orthodontic) and correct structural conditions of the jaw or face (orthognathic).
The Journal of Clinical Orthodontics published results from “Accelerated Orthodontics Using Pulsatile Forces in Orthognathic Surgical Patients,” a case series demonstrating accelerated treatment when incorporating AcceleDent into combined orthodontic and orthognathic surgery cases. In Case 1 of the series, Dr. Sharon Orton-Gibbs treated a 17-year-old male patient with AcceleDent. His estimated treatment time was 18-24 months, but with AcceleDent he completed treatment in 10.5 months.
Manufactured by OrthoAccel, AcceleDent is the first and only FDA-cleared vibratory orthodontic device that is clinically proven to speed up orthodontic treatment by as much as 50 percent. With peer-reviewed evidence that supports AcceleDent’s effectiveness in reducing discomfort as well as accelerating tooth movement and bone remodeling when used in conjunction with braces or aligners, this report is the first to publish results focused on AcceleDent’s use in multiple cases that combine orthodontic and orthognathic surgery.
AcceleDent employs patented SoftPulse Technology® that enhances physiological bone turnover enabling orthodontists to achieve predictable clinical outcomes. Primary author Dr. Sharon Orton-Gibbs, who began prescribing AcceleDent to patients in 2009, found that the mean actual treatment time for the 15 orthodontic-orthognathic surgery patients who used AcceleDent in conjunction with their fixed appliance braces was 33 percent shorter than the predicted treatment time (14.9 months vs. 22.2 months). Orton-Gibbs’ accurate treatment time predictions were discussed and verified in a previously published 2015 JCO article.1
“Prior to offering AcceleDent none of my surgery patients finished treatment in less than 16 months. With AcceleDent the fastest treatment time was eight and a half months,” said Orton-Gibbs, who is a highly regarded orthodontic specialist in the United Kingdom. “In my practice, treatment progressed faster and post-treatment healing was uneventful in orthognathic surgery patients who used AcceleDent.”
To accommodate for an estimated 30-50 percent reduction in treatment time with AcceleDent, Orton-Gibbs reduces the intervals between archwire changes by 25 -33 percent during leveling and aligning for her surgery cases and was able to see patients every five days for the five weeks after surgery, rather than the standard weekly appointments for six weeks.
“Since orthodontics cannot begin until bone growth is complete, surgery has the potential to extend treatment times,” said Orton-Gibbs. “That’s why I believe surgery patients are especially interested in accelerating treatment with AcceleDent.”
Reporting that 83 percent of her surgery patients chose to use AcceleDent, she also noted that two of the patients chose AcceleDent because they desired to complete treatment prior to relocating to attend university within the year. A third patient who is self employed chose AcceleDent to ensure that her surgery could be performed when she was least busy with work.
“We’re excited to add this publication to our growing clinical library and believe that Dr. Orton-Gibbs’ findings further demonstrate that AcceleDent’s pulsatile forces can enhance treatment efficiency and improve predictable clinical outcomes,” said Michael K. Lowe, president and CEO of OrthoAccel. “As the leader in accelerated orthodontics, we are committed to sharing compelling clinical evidence that demonstrates how AcceleDent can be successfully integrated into clinical practice with any preferred orthodontic appliance or treatment protocol.”
The article was published in the December issue of JCO and can be viewed here. In the article’s introduction Orton-Gibbs provides a synopsis of previously published peer-reviewed studies examining AcceleDent’s safety and effectiveness that may be of interest to orthodontists. For more information about clinically proven AcceleDent, visit AcceleDent.com.
About OrthoAccel® Technologies, Inc.
OrthoAccel® Technologies, Inc. is a privately owned medical device company engaged in the creation, manufacturing, marketing and sales of innovative solutions that enhance dental care and orthodontic treatment. Among the company’s innovations is AcceleDent®, an FDA-cleared, Class II medical device that employs patented SoftPulse Technology® that is clinically proven to speed up bone remodeling during orthodontic treatment by enhancing physiological bone turnover. These safe and gentle vibrations accelerate tooth movement by as much as 50 percent and reduce discomfort associated with treatment. OrthoAccel, the Leader in Accelerated Orthodontics, has received positive feedback from patients and leading orthodontists from around the world who report increased mechanical efficiency with orthodontic appliances and improved predictability of clinical outcomes with AcceleDent. Ranked on Deloitte’s 2015 Technology Fast 500 as one of the fastest growing companies in North America, OrthoAccel is based in Houston, Texas and maintains a global presence through its EMEA office in Essen, Germany. To learn more about OrthoAccel’s focus on improving the journey to healthy, beautiful smiles, visit AcceleDent.com.